Enhanced Phase II Efforts Paying Dividends, But At A Price, Pfizer Exec Says
Executive Summary
Expanded approaches to Phase II development have reduced Phase III attrition rates, but in doing so, have also created a new set of challenges for pharmaceutical companies, according to Pfizer Senior VP-Science & Technology Peter Corr
You may also be interested in...
Weeding Out Pipeline “Dogs” Early Can Be As Valuable As A Blockbuster
Eliminating "bad" compounds from the pipeline early in the development process can generate as much value as picking a blockbuster, McKinsey Partner Rodney Zemmel suggested Sept. 26
Weeding Out Pipeline “Dogs” Early Can Be As Valuable As A Blockbuster
Eliminating "bad" compounds from the pipeline early in the development process can generate as much value as picking a blockbuster, McKinsey Partner Rodney Zemmel suggested Sept. 26
QT Guidance Reducing Number Of Drugs Leaving Early Development, Firms Say
Stricter guidelines on QT prolongation are forcing manufacturers to drop compounds earlier in the development process, participants said during an FDA/Duke Cardiac Safety and Critical Path Initiative Think Tank meeting Oct. 11